^
Association details:
| Biomarker: | FBXW7 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer
Published date:
07/09/2020
Excerpt:
FBW7 mutations might be a potential biomarker predicting for response to the regorafenib/Mcl-1 inhibitor combination.
DOI:
10.7150/thno.45363
